Prime Medicine (PRME) Receivables (2024 - 2025)
Prime Medicine posted quarterly Receivables of $4.6 million for Q4 2025, up 185.02% year-on-year from $1.6 million in Q4 2024, and up 3721.67% on a QoQ basis from $120000.0 in Q2 2025.
Prime Medicine (PRME) has 2 years of Receivables data on file, last reported at $4.6 million in Q4 2025.
- For the quarter ending Q4 2025, Receivables rose 185.02% year-over-year to $4.6 million; the trailing twelve-month figure through Dec 2025 stood at $4.6 million (up 185.02% YoY), and the FY2025 full-year result was $4.6 million, up 185.02% from the prior year.
- Receivables for Q4 2025 stood at $4.6 million, up from $120000.0 in the prior quarter.
- Across five years, Receivables topped out at $55.0 million in Q3 2024 and bottomed at $17000.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Prime Medicine | 601.24 Mn | 601.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.59 Mn |
| Jun 30, 2025 | 120,000.00 |
| Mar 31, 2025 | 17,000.00 |
| Dec 31, 2024 | 1.61 Mn |
| Sep 30, 2024 | 55.00 Mn |